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Abstract
Objective: Burning mouth syndrome (BMS) is a complex disorder with a still uncertain etiopathogenesis. A 
number of treatments have been used in application to BMS, though without clearly successful results. The present 
study compares the improvement in BMS obtained as a result of different treatment modalities in relation to the 
clinical characteristics of the patients.
Study Design: A retrospective cohort study was made of 115 patients with BMS (109 females and 6 males) sub-
jected to different treatments with a view to improving the symptoms. The clinical variables examined included 
the duration of the disorder, the location of the burning sensation, its daily variations and relationship with meals. 
The parameters were measured using a visual analog scale (VAS) applied at baseline and again after two weeks 
of treatment.
Results: The mean patient age was 70±11.41 years, and the mean duration of the syndrome was 7.16±2.63 years. 
The tongue was the most frequently affected location. Anxiolytic treatment afforded the best results (p<0.001), 
and the patients with the shortest duration of disease showed the best improvement with treatment (p=0.005).
Conclusion: The greatest treatment efficacy corresponded to anxiolytic drugs, and treatment was more effective 
when introduced early after the diagnosis of BMS.
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Introduction
Burning mouth syndrome (BMS) is characterized by 
continuous burning sensation located in the apparent-
ly normal oral mucosa. It can be accompanied by dry 
mouth (xerostomia), taste alterations and other anoma-
lous sensations. The discomfort may be present from 
the morning or increase in the course of the day. The 
estimated prevalence of BMS is 0.7-4.6%, and the con-
dition mostly affects women of middle or advanced age 
(1). The etiopathogenesis of BMS remains unclear, and 
the different treatments used to date have shown little 
efficacy (2).
Psychological alterations such as anxiety and depres-
sion are often seen in these patients (3-7). Both process-
es can modulate pain perception, increasing or decreas-
ing neuronal conduction from the peripheral receptors, 
and modifying individual perception of discomfort. On 
the other hand, patients with BMS have been found to 
improve of their symptoms with the use of anxiolytic 
drugs or psychotherapy (8).
On the other hand, patients with BMS have been found 
to experience alterations in heat tolerance, taste distur-
bances and increased palpebral reflex excitability. This 
suggests the presence of alterations at both central and 
peripheral nervous system level (9). Neuropathic mech-
anisms have been identified, showing symptoms typi-
cal of alterations in the trigeminal domain. The clini-
cal characteristics of BMS in turn suggest the possible 
participation of neuronal inflammation in the etiopatho-
genesis of the syndrome, together with a series of other 
mechanisms (9,10).
Many treatments have been recommended for improv-
ing the symptoms of BMS, including sialogogues, topi-
cal anesthetics in rinses, anxiolytic drugs, antidepres-
sants, anticonvulsivants, alpha-lipoic acid and psycho-
therapy (8, 9-13), though no evidence has been produced 
by controlled clinical trials in support of such therapies. 
The best results have been reported for clonazepam, 
administered both topically and via the systemic route, 
though improvement has not been documented in all 
cases (14,15).
The present study was designed to evaluate the im-
provement afforded by different treatments in one same 
cohort of patients with BMS seen in the University 
Dental Clinic (Valencia University Medical and Dental 
School, Valencia, Spain), and to explore the relationship 
between the treatment provided and the clinical charac-
teristics of the syndrome, particularly as regards time.
Material and Methods
A retrospective cohort study was made of 115 patients 
with BMS (109 females and 6 males), seen in the Uni-
versity Dental Clinic for at least two years. Informed 
consent to participation in the study was obtained in all 
cases.
We included subjects with discomfort described as a 
burning or itching sensation of the oral mucosa for at 
least 6 months, and who presented no organic lesions at 
the time of initial exploration capable of accounting for 
the symptoms. Likewise, no prior laboratory test altera-
tions (biochemistry and hematology) were observed. 
All the patients had been treated for their oral symp-
toms and had been subjected to follow-up. As regards 
treatment, patients with dry mouth received sialogogues 
and artificial saliva formulations, while another group 
received palliative rinses in the form of 2% lidocaine 
solution, another was prescribed anxiolytic drugs (in 
all cases ketazolam 30 mg one capsule at bedtime), and 
another group received a topical 0.02% capsaicin for-
mulation.
The following exclusion criteria were considered at the 
time of diagnosis: subjects who at exploration showed 
specific lesions or systemic disease capable of account-
ing for the oral burning sensation; patients in which 
the symptoms had been present for under 6 months; 
patients with a very poor general condition who could 
present some serious illness precluding adequate explo-
ration and follow-up; and patients undergoing oncologi-
cal treatment.
The personal and clinical data of each patient were re-
corded, with special emphasis on the duration of the 
syndrome, the location of the burning sensation in the 
oral cavity, the associated discomfort, daily variations 
and relationship with meals.
The intensity of discomfort was measured using a vis-
ual analog scale (VAS) scored from 0 to 10 cm, where 
0 = no symptoms and 10 = unbearable discomfort. The 
VAS was applied at baseline and again after two weeks 
of treatment.
Results
In this study, 92.17% of the patients with BMS were fe-
males, while only 7.82% were males (10/1 proportion). 
The mean age was 70.96±11.41 years (range 37-98).
(Table 1) shows the patient age distribution by decades. 
The overall mean duration of the disease was 7.16±2.63 
years (range 1-24)(percentile 50 corresponding to 5 
years). Most of the patients (90.4%; n=104) referred no 
toxic habits. None of the subjects were regular alcohol 
consumers, and only 11 were smokers.
As regards medication history, 34 patients (29.6%) were 
receiving no medication at the time of the first visit. In 
relation to the drugs used at the time of this visit 47.8% 
received anxiolytic drugs (n=55) and 21.7% antidepres-
sants (n=25). In turn, 29 patients used oral antidiabetic 
drugs and 26 were prescribed blood pressure-lowering 
medication.
The tongue was the most common location of burning 
sensation (56 patients), while the oral cavity in general 
was found to be affected in 24 subjects. Other locations 
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were the lips, gums and cheek mucosa (20%). Of note is 
the observation that the lower lip was affected in 10.4% 
of the cases.
The most frequent accompanying manifestation was 
dry mouth (xerostomia) (64.3%), followed by taste al-
terations (50.4%).
Regarding the treatment provided for BMS, 40 patients 
used anxiolytic drugs (34.8%), 24 cases received 2% 
lidocaine rinses (20.9%), 22 used sialogogues (19.1%), 
11 used artificial saliva (9.6%), and 18 patients used 
topical capsaicin gel (15.7%).
The VAS score at baseline (before specific treatment) 
ranged from 6-10, while the most frequent score was 
8 (mode). The scores were seen to decrease after treat-
ment, with complete disappearance of discomfort in 
two cases. In the subjects administered anxiolytic treat-
ment, the VAS scores decreased three or more points 
with respect to baseline – the difference versus the rest 
of treatments being statistically significant (x2=32.29, 
p<0.001) (Fig. 1).
Fig. 1. Improvements in VAS symptoms score after treatment for burning mouth syndrome.
Legends to columns:
1.Anxiolytics
1.Sialogogues
3.2% lidocaine rinse
4.Artificial saliva
5.Topical capsaicin
Age n(%) 
30-39 years 2 (1.73%) 
40-49 years 4 (3.4%) 
50-59 years 15 (13.04%) 
60-69 years 24 (20.86%) 
70-79 years 43 (37.39%) 
80-89 years 19 (16.52%) 
90-99 years 8 (6.95%) 
Table 1. Patient age distribution by 
decades.
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Score improvements of under three points were record-
ed in 72 cases (62.6%), while improvements of three or 
more points were recorded in 43 patients (37.4%) in the 
total study sample (n=115).
No significant associations were observed between the 
variations in oral symptoms intensity and patient age or 
gender. Likewise, no significant relationship was noted 
between the variation in VAS score with specific treat-
ment and other variables such as the location of burning 
sensation, the accompanying symptoms, daily varia-
tions or relationship with meals. 
The patients with the shortest duration of BMS (< 2 
years) showed greater improvement with treatment (> 
4 points on the VAS)(Fisher’s exact test, p=0.005) (Fig. 
2).
On examining the association between the variation 
in symptoms intensity and the type of medication ad-
ministered, the greatest decrease in discomfort was 
seen to correspond to the patients administered anxi-
olytic drugs (p<0.01), followed by capsaicin (x2=41.35, 
p<0.01). No significant results were obtained in relation 
to the rest of treatments. Anxiolytics and capsaicin af-
forded a reduction in VAS score of three or more points 
in 72.5% and 44.4% of the patients administered these 
drugs, respectively.
Fig. 2. Duration of burning mouth syndrome (years) in relation to symptoms improvement with treatment (over or 
under 4 points on the VAS).
Discussion
The results of this study show that the sooner treatment is 
prescribed after the diagnosis of burning mouth syndrome 
(BMS), the better the results obtained. In this sense, a 
mean improvement in VAS symptoms score of two points 
was recorded when the patients were treated in under four 
years after the diagnosis, and in one-third of the cases the 
improvement was three points or more. However, it must 
be taken into account that this was a retrospective study in 
which not all the treatments prescribed were equally ef-
fective in application to BMS. According to Sardella et al. 
(16), less than 30% of all patients experience improvement 
as a result of different treatments, and spontaneous remis-
sion in the first 5 years after the diagnosis is minimal. In 
our series, over 37% of the subjects experienced clear im-
provement (> 3 points on the VAS).
The management of BMS has been quite disappointing to 
date – this in part being due to our lack of knowledge of 
the specific mechanisms underlying the syndrome (14). 
Of the different treatments evaluated in our study, anxi-
olytic drugs were found to be the most effective option, 
affording a decrease in VAS score of three or more points 
in almost two-third of all cases, followed by topical cap-
saicin. Other authors (1, 15-17) have published controver-
sial results with the administration of anxiolytic drugs.
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The highest incidence of BMS corresponded to elderly 
females with a mean age of almost 71 years. No direct 
relationship was found between improvement with 
therapy and patient age, though there was a tendency 
towards lesser improvement in very elderly women 
compared with younger females.
The most common systemic diseases in our series were 
psychiatric problems in the form of anxiety and de-
pression, followed by arterial hypertension and type 2 
diabetes. Although references have been made to BMS 
comorbidity, these conditions clearly can be explained 
by the advanced age of the patients.
The symptoms of BMS tend to become chronic. This 
complicates patient management and gives rise to sit-
uations similar to those found in chronic pain, where 
symptoms persistence over time gives rise to increased 
anxiety and depression.
Few studies have provided information on the spontane-
ous remission of BMS symptoms (15,18,19), though in 
any case such remission must be very infrequent.
At present there is sufficient evidence of neuropathic in-
volvement in this syndrome. Abnormal patient percep-
tion of certain nociceptive stimuli has been reported, 
with alterations of the trigeminal transmission small C 
fibers, and the appearance of inflammatory neuropep-
tides in the saliva of patients with BMS (20,21). These 
findings suggest alterations in the sensory function of 
the trigeminal system in BMS. Likewise, an altered 
palpebral reflex has been reported, as well as extrapy-
ramidal alterations with failure of dopaminergic inhibi-
tory control in the basal ganglia (22).
On the other hand, patients with BMS are known to 
have an important presence of anxiety and depression, 
though it is difficult to establish Gao et al. (23), psy-
chopathological factors together with local irritative 
elements may favor the appearance of BMS symptoms 
over time.
Treatment success has also been related to these etio-
pathogenic theories. Clonazepam has been found to be 
effective (both topically and via the systemic route) in 
improving the symptoms of BMS. Anxiolytic drugs are 
also able to improve the symptoms, as observed in our 
own patients.
Burning mouth is a complex clinical condition, though 
there is sufficient evidence to allow a more effective ap-
proach to the disease. In this sense, we consider that 
topical clonazepam should be combined with the use 
of anxiolytic drugs (ketazolam) in the presence of an 
important anxiolytic component, and that treatment 
should be started as soon as possible after the diagnosis 
of BMS.
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